ArticleScientific reports2020
In vitro synergy of isavuconazole in combination with colistin against Candida auris.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Colistin enhances caspofungin antifungal efficacy against Aspergillus fumigatus by modulating calcium homeostasis and stress responses.Nature communications · 2025Article
- Isolate Specific Transcriptome Changes Exerted by Isavuconazole Treatment in Candida auris.Mycopathologia · 2024Article
- Azole Combinations and Multi-Targeting Drugs That Synergistically InhibitJournal of fungi (Basel, Switzerland) · 2024Review
- Synergistic Activity of Ingulados Bacteria with Antibiotics against Multidrug-Resistant Pathogens.Antibiotics (Basel, Switzerland) · 2024Article
- Clorgyline Analogs Synergize with Azoles against Drug Efflux inJournal of fungi (Basel, Switzerland) · 2023Article
- PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris.CPT: pharmacometrics & systems pharmacology · 2023Article
- Structural Characterization, Cytotoxicity, and the Antifungal Mechanism of a Novel Peptide Extracted from Garlic (Molecules (Basel, Switzerland) · 2023Article
- Small molecules for combating multidrug-resistant superbugActa pharmaceutica Sinica. B · 2022Review
- Synergistic In Vitro Interaction of Isavuconazole and Isoquercitrin againstJournal of fungi (Basel, Switzerland) · 2022Article
- Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Emerging and future strategies in the management of recalcitrant Candida auris.Medical mycology · 2022Review
- In Vitro Activity of Amphotericin B in Combination with Colistin against Fungi Responsible for Invasive Infections.Journal of fungi (Basel, Switzerland) · 2022Article
- Article
- In vitro and in vivo interaction of caspofungin with isavuconazole against Candida auris planktonic cells and biofilms.Medical mycology · 2021Article
- The Negative Effect of Protein Phosphatase Z1 Deletion on the Oxidative Stress Tolerance ofJournal of fungi (Basel, Switzerland) · 2021Article
- In Vitro Synergistic Interactions of Isavuconazole and Echinocandins againstAntibiotics (Basel, Switzerland) · 2021Article
- Promising Drug Candidates and New Strategies for Fighting against the Emerging SuperbugMicroorganisms · 2021Review
- Combining Colistin and Fluconazole Synergistically Increases Fungal Membrane Permeability and Antifungal Cidality.ACS infectious diseases · 2021Article
- Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.Journal of fungi (Basel, Switzerland) · 2021Review
- Colistin and Isavuconazole Interact Synergistically In Vitro againstMicroorganisms · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vitro interactions of isavuconazole with colistin were evaluated against 15 clinical Candida auris isolates by a microdilution checkerboard technique based on the EUCAST reference method for antifungal susceptibility testing and by agar diffusion using isavuconazole gradient concentration strips with or without colistin incorporated RPMI agar. Interpretation of the checkerboard results was done by the fractional inhibitory concentration index and by response surface analysis based on the Bliss model. By checkerboard, combination was synergistic for 93% of the isolates when interpretation of the data was done by fractional inhibitory concentration index, and for 80% of the isolates by response surface analysis interpretation. By agar diffusion test, although all MICs in combination decreased compared to isavuconazole alone, only 13% of the isolates met the definition of synergy. Essential agreement of EUCAST and gradient concentration strip MICs at +/- 2 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.